Data from Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i>

Abstract

&lt;div&gt;Abstract&lt;p&gt;Germline mutations in &lt;i&gt;BRCA1/2&lt;/i&gt; are risk factors for pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to evaluate whether results of surveillance for PDAC in high risk individuals (HRI) differ between those with and without a pathogenic &lt;i&gt;BRCA1/2&lt;/i&gt; mutation. This prospective study was conducted within the Pancreatic Tumor Registry at a major cancer center. There were 83 HRIs with ≥1 first-degree relative with PDAC who underwent surveillance and testing for pathogenic germline mutations in &lt;i&gt;BRCA1/2&lt;/i&gt;. A secondary analysis includes 18 HRIs with known mutations in &lt;i&gt;BRCA1/2&lt;/i&gt; but with weaker family history. HRIs were evaluated over time using magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound when indicated by MRCP findings. We reviewed imaging results, blinded to mutation status. Demographic information was obtained from interviewer-administered questionnaires. The outcome was the proportion with any pancreatic abnormality identified at initial or follow-up surveillance. Among the 83 HRIs in the main analysis, 48 had a mutation in &lt;i&gt;BRCA1/2&lt;/i&gt; and 35 did not. Overall, 16 of 48 (33%) &lt;i&gt;BRCA1/2&lt;/i&gt;-positive and 13 of 35 (37%) &lt;i&gt;BRCA1/2&lt;/i&gt;-negative participants had pancreatic abnormalities on imaging; in each group, all but one finding was an intraductal papillary mucinous neoplasm. Among those with pathogenic mutations but weaker family history, results were similar: 7 of 18 (39%) with pancreatic abnormalities. Results of surveillance for pancreatic abnormalities on imaging are similar regardless of &lt;i&gt;BRCA1/2&lt;/i&gt; mutation status. While the results from this small study need confirmation in other studies, at present there does not appear to be increased yield from targeting individuals with &lt;i&gt;BRCA1/2&lt;/i&gt; mutations for surveillance.&lt;/p&gt;&lt;/div&gt;